| scholarly article | Q13442814 |
| P50 | author | Martin C Taylor | Q42172320 |
| P2093 | author name string | Michael D Lewis | |
| John M Kelly | |||
| Amanda Fortes Francisco | |||
| Shiromani Jayawardhana | |||
| P2860 | cites work | Red-emitting luciferases for bioluminescence reporter and imaging applications. | Q39800473 |
| Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. | Q42215365 | ||
| T-cell molecular mimicry in Chagas disease: identification and partial structural analysis of multiple cross-reactive epitopes between Trypanosoma cruzi B13 and cardiac myosin heavy chain | Q42653469 | ||
| Benznidazole prevents endothelial damage in an experimental model of Chagas disease. | Q44480610 | ||
| Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial | Q47708871 | ||
| 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection | Q48342608 | ||
| What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment | Q48530669 | ||
| Trypanosoma cruzi infection induces a massive extrafollicular and follicular splenic B-cell response which is a high source of non-parasite-specific antibodies. | Q50559773 | ||
| Trypanosoma cruzi: differentiation after interaction of epimastigotes and Triatoma infestans intestinal homogenate. | Q52457794 | ||
| Chagas’ Disease | Q57985265 | ||
| Chagas disease | Q58842312 | ||
| Amplification of a Trypanosoma cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy | Q58844325 | ||
| New, improved treatments for Chagas disease: from the R&D pipeline to the patients | Q21092295 | ||
| Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection | Q24194546 | ||
| A new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in vivo imaging | Q27011506 | ||
| CD8+ T cells in Trypanosoma cruzi infection | Q28081766 | ||
| Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease | Q28548342 | ||
| Transient regenerative potential of the neonatal mouse heart | Q29620371 | ||
| Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease | Q34108634 | ||
| Chagas disease cardiomyopathy: immunopathology and genetics | Q34125557 | ||
| Parasite persistence in the aetiology of Chagas disease | Q34240113 | ||
| Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection | Q34310471 | ||
| Chagas' heart disease: clinical-pathological correlation | Q35011251 | ||
| Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis | Q35095569 | ||
| Trypanosoma cruzi and Chagas' Disease in the United States | Q35361594 | ||
| Impact of benznidazole on infection course in mice experimentally infected with Trypanosoma cruzi I, II, and IV | Q35692509 | ||
| A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes | Q36516224 | ||
| Host and parasite genetics shape a link between Trypanosoma cruzi infection dynamics and chronic cardiomyopathy | Q37272449 | ||
| Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage | Q37342932 | ||
| Trypanocidal drugs: mechanisms, resistance and new targets | Q37623081 | ||
| Chagas disease and stroke | Q37732618 | ||
| Review: surveillance of Chagas disease | Q38021060 | ||
| Diagnosis and management of Chagas disease and cardiomyopathy | Q38030830 | ||
| Autoimmune pathogenesis of Chagas heart disease: looking back, looking ahead | Q38412987 | ||
| Immunity and immune modulation in Trypanosoma cruzi infection | Q38599837 | ||
| Current and Future Chemotherapy for Chagas Disease | Q38610293 | ||
| Putting Infection Dynamics at the Heart of Chagas Disease | Q38950397 | ||
| Biological factors that impinge on Chagas disease drug development | Q39010376 | ||
| Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population | Q39242262 | ||
| Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial | Q39269371 | ||
| Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy | Q39269382 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pathology | Q7208 |
| pharmacology | Q128406 | ||
| infectious disease | Q18123741 | ||
| benznidazole | Q425300 | ||
| Chagas disease | Q649558 | ||
| P577 | publication date | 2018-10-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Assessing the Effectiveness of Curative Benznidazole Treatment in Preventing Chronic Cardiac Pathology in Experimental Models of Chagas Disease | |
| P478 | volume | 62 |
| Q92765270 | Low-Level Parasite Persistence Drives Vasculitis and Myositis in Skeletal Muscle of Mice Chronically Infected with Trypanosoma cruzi | cites work | P2860 |
Search more.